Clinical Trials Directory

Trials / Completed

CompletedNCT05533606

Risk Factors and Machine Learning Model for Beta-Lactam Drugs Related Acute Kidney Injury

Analysis of Risk Factors of Beta-Lactam Drugs Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model

Status
Completed
Phase
Study type
Observational
Enrollment
19,000 (actual)
Sponsor
Qianfoshan Hospital · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.

Conditions

Interventions

TypeNameDescription
DRUGBeta-Lactam DrugsDuring hospitalization,patients used Beta-Lactam drugs.

Timeline

Start date
2022-07-01
Primary completion
2023-06-30
Completion
2023-06-30
First posted
2022-09-09
Last updated
2023-11-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05533606. Inclusion in this directory is not an endorsement.